On assessing potential efficacy for vortioxetine in generalized anxiety disorder

European Neuropsychopharmacology

Volumn 22, Issue 12, 2012, Pages 841-843

  Baldwin, David S ^a   Nutt, David J ^b  

^a UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^b IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

DULOXETINE; LUAA 21004; PLACEBO; UNCLASSIFIED DRUG; VORTIOXETINE;

DRUG EFFICACY; DRUG WITHDRAWAL; EDITORIAL; FOLLOW UP; GENERALIZED ANXIETY DISORDER; HUMAN; MAJOR DEPRESSION; PATIENT COMPLIANCE; PRIORITY JOURNAL; PSYCHOPHARMACOTHERAPY; SYMPTOM;

ANTI-ANXIETY AGENTS; ANXIETY DISORDERS; CLINICAL TRIALS AS TOPIC; HUMANS; PIPERAZINES; SULFIDES; TREATMENT OUTCOME;

EID: 84870656338     PISSN: 0924977X     EISSN: 18737862     Source Type: Journal    
DOI: 10.1016/j.euroneuro.2012.07.018     Document Type: Editorial

References (18)

1. Alvarez E., Perez V., Dragheim M., Loft H., Artigas F. A double-blind, randomized, placebo-controlled, active reference study of Lu AA21004 in subjects with major depressive disorder. Int. J. Neuropsychopharmacol. 2012, 15:589-600.
2. Baldwin D.S., Waldman S., Allgulander C. Evidence-based pharmacological treatment of generalized anxiety disorder. Int. J. Neuropsychopharmacol. 2011, 14:697-710.
3. Baldwin D.S. Where is the room for improvement in the drug treatment of depression and anxiety?. Hum. Psychopharmacol. 2011, 26:1-3.
4. Baldwin D.S., Loft H., Florea I. Lu AA21004, a multimodal psychotropic agent, in the prevention of relapse in adult patients with generalized anxiety disorder. Int. Clin. Psychopharmacol. 2012, 27:197-207.
5. Baldwin D.S., Loft H., Dragheim M. A randomised, double-blind, placebo controlled, duloxetine-referenced, fixed-dose study of three dosages of LuAA21004 in acute treatment of major depressive disorder (MDD). Eur. Neuropsychopharmacol. 2012, 22:482-491.
6. Ballaz S.J., Akil H., Watson S.J. The 5-HT7 receptor: role in novel object discriminationand relation to novelty-seeking behaviour. Neuroscience 2007, 149:192-202.
7. Bang-Andersen B., Ruhland T., Jorgensen M., Smith G., Frederiksen K., Jensen K.G. Discovery of 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine (Lu AA21004): a multimodal compound for the treatment of major depressive disorder. J. Med. Chem. 2011, 54:3206-3321.
8. Bidzan, L., Mahableshwarkar, A.R., Jacobsen, P., Yan, M., Sheehan, D.V. Vortioxetine (Lu AA21004) in generalized anxiety disorder: results of an 8-week, multinational, randomized, double-blind, placebo-controlled clinical trial. Eur. Neuropsychopharmacol,, in press. http://dx.doi.org/10.1016/j.euroneuro.2012.07.012.
9. Boulenger J-P., Loft H., Florea I. A randomized clinical study of Lu AA21004 in the prevention of relapse in patients with major depressive disorder. J. Psychopharmacol. 2012, (E-pub ahead of print).
10. Burzykowski T., Carpenter J., Coens C., Evans D., France L., et al. Missing data: discussion points from the PSI missing data expert group. Pharm. Statist. 2010, 9:288-297.
11. Henigsberg N., Mahableshwarkar A.R., Jacobsen P., Chen Y., Thase M.E. Efficacy and safety of multiple doses of Lu AA21004 in an 8-week treatment of adults with major depressive disorder. Eur. Neuropsychopharmacol. 2011, 21(Suppl. 3):S393.
12. Jain, R., Mahableshwarkar, A.R., Jacobsen, P., Chen, Y., Thase, M.E., 2011. Efficacy and tolerability of Lu AA21004 5mg in a 6-week treatment of adults with major depressive disorder. Poster Presentation, Annual Meeting of the American Psychiatric Association, Honolulu, Hawaii, USA, May 14-18, 2011.
13. Katona C., Hansen T., Olsen C.K. A randomized, double-blind, placebo-controlled, duloxetine-reference, fixed-dose study comparing the efficacy and safety of Lu AA21004 in elderly patients with major depressive disorder. Int. Clin. Psychopharmacol. 2012, 27:215-223.
14. Khan A., Khan S., Brown W.A. Are placebo controls necessary to test new antidepressants and anxiolytics?. Int. J. Neuropsychopharmacol. 2002, 5:193-197.
15. Khin N.A., Chen Y.-F., Yang Y., Yang P., Laughren T.P. Exploratory analyses of efficacy data from major depressive disorder trials submitted to the US Food and Drug Administration in support of new drug applications. J. Clin. Psychiatry 2011, 72:464-472.
16. Lane P. Handling drop-out in longitudinal clinical trials: a comparison of the LOCF and MMRM approaches. Pharm. Stat. 2008, 7:93-106.
17. Rothschild, A.J., Mahableshwarkar, A.R., Jacobsen, P., Yan, M., Sheehan, D.V. Vortioxetine (Lu AA21004) 5mgingeneralized anxiety disorder: results of an 8-week, randomized, doubleblind, placebo-controlled clinical trial in the United States. Eur. Neuropsychopharmacol,, in press. http://dx.doi.org/10.1016/j.euroneuro.2012.07.011.
18. Siddiqui O., Hung H.M., O'Neill R. MMRM vs. LOCF: a comprehensive comparison based on simulation study and 25 NDA datasets. J. Biopharm. Stat. 2009, 19:227-246.